

ibandronic acid (Bondronat®) HCM
Roche

(No. 122/04)

Indication: Hypercalcaemia of malignancy

Summary of Advice

11 October 2004

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and ADTCs on its use in NHS Scotland. The advice is summarised as follows:

ADVICE: following a full submission.

Ibandronic acid is accepted for use within NHS Scotland for the treatment of tumour-induced hypercalcaemia with or without metastases.

It has been shown to be a cost-effective option in reducing serum calcium in patients with hypercalcaemia of malignancy.

Professor David H Lawson
Chairman